Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile

Journal of Endocrinological Investigation

Volumn 28, Issue 3, 2005, Pages 49-53

  Zulian, E ^a   Sartorato, P ^a   Benedini, S ^a   Baro, G ^a   Armanini, D ^a   Mantero, F ^a   Scaroni, C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

HOMA; Insulin resistance; Lipid profile; Polycystic ovary syndrome; Spironolactone

Indexed keywords

SPIRONOLACTONE; ANTIANDROGEN; INSULIN; LIPID;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HOMEOSTASIS; HUMAN; HYPERANDROGENISM; INSULIN RELEASE; INSULIN SENSITIVITY; LIFESTYLE; METABOLIC PARAMETERS; OLIGOMENORRHEA; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PROSPECTIVE STUDY; WEIGHT REDUCTION; AREA UNDER THE CURVE; BLOOD; BODY MASS; CALORIC RESTRICTION; CLINICAL TRIAL; DIET; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; AREA UNDER CURVE; BODY MASS INDEX; CALORIC RESTRICTION; DIET; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; OBESITY; POLYCYSTIC OVARY SYNDROME; SPIRONOLACTONE;

EID: 21344437501     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345529     Document Type: Article

References (20)

1. Azziz R, Saenger P. The Second International Symposium on the Developmental Aspects of Androgen Excess, Toronto, Canada, 20 June 2000. Trends Endocrinol Metab 2000, 11: 338-40.
2. Legro RS. Polycystic ovary syndrome: the new millennium. Mol Cell Endocrinol 2001, 184: 87-93.
3. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84: 165-9.
4. Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev 1991, 12: 3-13.
5. Giudice LC. The insulin-like growth factor system in normal and abnormal human ovarian follicle development. Am J Med 1995, 98: 485-545.
6. Diamanti-Kandarakis E. How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome? J Endocrinol Invest 1998, 21: 623-9.
7. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001, 28: 111-3.
8. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health 1951, 41: 279-81.
9. Pasquali R, Antenucci D, Casimirri F. Clinical and hormonal characteristics of obese and amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989, 68: 173-89.
10. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992, 36: 101-11.
11. Krowchuk DP, Lucky AW. Managing adolescent acne. Adolesc Med 2001, 12: 355-74.
12. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977, 97: 247-54.
13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cells function from fasting plasma glucose and insulin concentrations in men. Diabetologia 1985, 28: 412-9.
14. Diamanti-Kandarakis E, Tolis G, Duleba A. Androgens and therapeutic aspects of antiandrogens in women. J Soc Gynecol Invest 1995, 2: 577-92.
15. Cumming DC, Yang JC, Rebar RW, Yen SS. Treatment of hirsutism with spironolactone. JAMA 1982, 247: 1295-8.
16. Moghetti P, Tosi F, Castello R, et al. The insulin-resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment; evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996, 81: 952-60.
17. Gokmen O, Senoz S, Gulekli B, Isik AZ. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome. Gynecol Endocrinol 1996, 10: 249-55.
18. Wild RA, Demers LM, Applebaum-Bowden D, Lenker R. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone. Contraception 1991, 44: 113-24.
19. Vrbikova J, Cibula D, Dvorakova K et al. Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89: 2942-5.
20. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycyst ovary syndrome. Diabetes 1989, 38: 1165-74.